Alpha Healthcare Acquisition Corp. III
ALPA
NASDAQ Capital Market9.80
USD
+0.01
- -
CIK
0001842939
ISIN
US02073F1049
CUSIP
02073F104
Return %
Stock
S&P500
1Y
0.62
26.53
3Y
0.51
76.60
5Y
0.51
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Rajiv Sarman Shukla
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1177 Avenue of the Americas New York City NY United States of America 10036
- IPO Date
- Sep 23, 2021
- CIK
- 0001842939
- Website
- alphaspac.com
- Similar Companies
- Business
- Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) is a special purpose acquisition company (SPAC) formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses primarily in the healthcare industry, with a focus on healthcare and life sciences companies having market capitalizations between $500 million and $1.5 billion. The company raised approximately $250 million in gross proceeds from its initial public offering in October 2021 and targets sectors including biotechnology, medical technology, healthcare services, healthcare IT, and regenerative medicine. It does not have operating products or services of its own but provides merger and acquisition services to facilitate public listings for private healthcare entities through de-SPAC transactions. Alpha Healthcare Acquisition Corp. III, founded in 2021 and headquartered at 1177 Avenue of the Americas, 5th Floor, New York, New York, operates principally in the United States with a strategic emphasis on North American healthcare markets. Led by Executive Chairman Rajiv Shukla, who brings over two decades of healthcare investment and operational experience, the company pursues opportunities in high-growth areas such as active soft tissue repair, aesthetics, orthopedics, and diabetic wound care. In July 2023, the company completed its initial business combination with Carmell Therapeutics Corporation, a Phase 2-stage regenerative medicine platform company developing allogeneic plasma-based biomaterials; post-merger, the combined entity trades under the ticker CTCX on Nasdaq, with ALPA trust retaining approximately $29.4 million in gross proceeds after redemptions. Prior to closing, in May 2023, Alpha Healthcare Acquisition Corp. III signed a non-binding letter of intent to acquire a commercial-stage regenerative medicine company specializing in human allograft products for tissue repair, aesthetic treatments, and orthopedic applications, conditioned upon the Carmell transaction completion. No further major acquisitions, funding rounds, or strategic shifts have been publicly announced since the 2023 Carmell merger.
ALPA Moves To Cut Dues As American Pilots Mull Vote On Joining ALPA
American Airlines Pilots Seem To Waiver On Desire To Join ALPA
American Airlines Pilots Move Towards Vote On Whether To Join ALPA
Amerijet International Airlines reaches agreement with their Pilots represented by ALPA
A Vote For ALPA President Is Set For Wednesday, With Delta And United Captains As Candidates